Therapeutic Goods (Standard for Blood and Blood Components) (TGO 102) Order 2019

This Order relies on a small set of definitional and structural choices that determine its practical effect. The text defines the core objects and the normative sources, then layers two express additional requirements onto the adopted Guide.

Definitions and adopted documents

• Blood is defined narrowly as "whole blood collected from a single human donor and processed either for transfusion or further manufacturing" (s 4, definition of blood). That ties the standard to whole blood collections intended for transfusion or further processing, not to other biological materials.
• Blood components are enumerated (red cells, white cells, platelets, plasma) and limited to components "that can be prepared by centrifugation, filtration or freezing using conventional methodologies in blood establishment" (s 4, definition of blood components). The definition excludes haematopoietic progenitor cells (s 4).
• The Guide (Council of Europe Guide, 19th edition, 2017) is adopted by reference, "as in force or existing immediately before the commencement of this instrument" (s 4). The instrument therefore incorporates an external, pre-commencement technical standard rather than reproducing it in full.

Scope and exclusions

• The instrument applies to "therapeutic goods that are blood and blood components" (s 6(1)), but three exclusions in s 6(2) remove from application blood collected or manufactured in the course of diagnosis/treatment by a registered medical practitioner or by a blood donation centre for a practitioner’s particular patient. Each exclusion hinges on the person being a "medical practitioner, registered under a law of a State or Territory", or a person acting under their professional supervision (s 6(2)(a)-(c)). The instrument therefore defers to state/territory registration and professional supervision concepts for those carve outs.

Substantive requirements

• The instrument makes the Guide's requirements binding subject to one textual modification (s 7(1)-(2)). Section 7(2) alters the Guide's reference to "tropical areas" in the deferral table so that "tropical areas" do not include areas within Australia. That is a specific national calibration of an imported standard.
• Section 7(3) requires that blood and blood components must only be manufactured from blood where samples test negative for HBV, HCV and HIV-1 using nucleic acid amplification technology. The requirement specifies the infectious agents and the testing methodology.
• Section 7(4) prohibits manufacturing from donors who meet specified historical residency or transfusion/injection criteria relating to England, Scotland, Wales, Northern Ireland or the Isle of Man, with precise temporal bounds (s 7(4)(a)-(b)). The clause uses cumulative residency of six months or more between 1 January 1980 and 31 December 1996, and transfusion/injection after 1 January 1980. Note that the instrument text refers to "Northern Island" at s 7(4)(b) as printed.

Transitional and amendment architecture

• The prior standard, TGO 81, is expressly repealed (Schedule 1; s 9). A transitional period (31 March 2019 to 30 March 2020) permits conformance with the former instrument as an alternative to the new standard (s 8). This dual-conformance window modifies the immediate compliance environment.
• A consequential amendment substitutes the new instrument’s title into the Technical Master File definition in the Therapeutic Goods (Manufacturing Principles) Determination 2018 (Schedule 2; s 10). That updates one cross-reference in the manufacturing principles.

Authority and commencement

• The instrument is made under ss 10 and 36 of the Therapeutic Goods Act 1989 (s 3). It specifies a single commencement date, 31 March 2019, for the whole instrument (s 2).

These structural elements determine the instrument's reach: it imports an external technical Guide, adds three discrete statutory modifications, sets precise donor and testing rules, carves out practitioner-use contexts, and provides a short transition period during which the old standard remains an acceptable alternative.

The instrument’s language and operative provisions identify a narrow universe of affected actors and institutions, and also specify actors excluded from application.

Primary affected parties

• Manufacturers and blood establishments that supply therapeutic goods consisting of blood and blood components are directly affected. Section 6(1) states the instrument applies to therapeutic goods that are blood and blood components. Section 4's definitions link those terms to whole blood and specific blood components prepared by conventional methodologies in blood establishments. Entities that "manufacture" within the Act’s meaning and produce blood-derived therapeutic goods must therefore comply with the requirements in s 7.
• Organisations that operate blood establishments will be operationally affected by the requirement in s 7(3) to use nucleic acid amplification technology to test samples for HBV, HCV and HIV-1 and by the donor exclusion rules in s 7(4). Those are procedural constraints that will affect donor selection, screening, testing pathways and batch release decisions.

Secondary affected parties

• Clinical transfusion services, hospital blood banks and laboratories involved in the processing and release of blood and blood components are operationally implicated because they are part of the manufacture, processing or quality assurance chain for therapeutic goods.
• Technical master file holders and manufacturing documentation will be affected by the consequential amendment in Schedule 2, which updates a cross-reference in the Therapeutic Goods (Manufacturing Principles) Determination 2018 to reflect the new instrument.

Parties expressly excluded or carved out

• Section 6(2) provides three exclusions. The standard does not apply to:
  • blood collected by a registered medical practitioner, or a person under their professional supervision, in the course of medical treatment and for diagnosis/testing purposes (s 6(2)(a));
  • blood manufactured by a registered medical practitioner, or under their supervision, for therapeutic application to a patient under that practitioner’s care (s 6(2)(b)); and
  • blood manufactured by a blood donation centre for a registered medical practitioner for application to a particular patient under the practitioner’s care (s 6(2)(c)).
• These carve outs link application to the practitioner's registration under state or territory law; the instrument therefore draws the bounds of federal standard application at the point where treatment, patient-specific manufacture or practitioner-supervised activity occurs.

Regulatory actors and decision-makers

• The instrument was made by a delegate of the Minister for Health (front matter lists Jane Cook as the delegate who made the Order). It is made under federal statutory powers in ss 10 and 36 of the Therapeutic Goods Act 1989 (s 3). The instrument itself does not designate compliance officers, inspectors, or sanctioning processes; such enforcement would be executed under the Act’s provisions, which are not reproduced here.

Indirectly affected groups

• Donors are affected by the eligibility criteria in s 7(4) and by any donor deferral policies derived from the adopted Guide and modified in s 7(2). The donor pool available to blood establishments may change in composition because of the specified exclusions and test requirements.
• Healthcare providers who rely on availability of particular blood components may be indirectly affected by any operational or supply consequences arising from donor exclusions or testing requirements.

Who pays and who decides

• The instrument prescribes actions (testing, exclusion) but does not specify cost allocation or reimbursement arrangements. By operation, the obligations fall on those who manufacture the therapeutic goods (s 6(1), s 7), so they bear the compliance and operational costs unless other arrangements exist outside the instrument. Decisions about applicability of the carve outs hinge on whether a practitioner is "registered under a law of a State or Territory" and whether blood is collected or manufactured "in the course of medical treatment" or "for a particular patient", facts that will be decided by manufacturers, medical practitioners and regulators in the ordinary course.

Geographic reach and temporal limits

• The instrument applies across Australia from its commencement date (s 2) and incorporates an external Guide version fixed to the state immediately before commencement (s 4). The donor exclusions in s 7(4) reference historical residency and transfusion events in specific foreign jurisdictions and a fixed historical date range; they therefore create donor-eligibility rules that turn on past activities and historical dates.

In sum, the instrument primarily affects manufacturers and blood establishments, with practical knock-on effects for laboratories, transfusion services and donors, while excluding practitioner-managed clinical collections and patient-specific manufacture where a registered medical practitioner is responsible.

The Order creates a compact set of duties (legal obligations) for entities manufacturing blood and blood components, and it establishes certain rights implicitly by carving out exceptions and setting alternative compliance pathways for a transition period.

Primary duties

• Conformity with the Guide as incorporated: Section 7(1)(a) makes the requirements "those specified in the Guide", subject to the statutory modifications that follow. Conformity with the Guide therefore becomes the principal duty. The Guide adopted is the Council of Europe Guide to the preparation, use and quality assurance of blood components, 19th edition, 2017, "as in force or existing immediately before the commencement of this instrument" (s 4). The duty to comply therefore depends on the content of that edition.
• Specific testing duty: Section 7(3) imposes an express statutory duty that blood and blood components "must only be manufactured from blood where samples of that blood test negative for HBV, HCV and HIV-1, using nucleic acid amplification technology." That is prescriptive: manufacturers must ensure negative NAT results for these three agents before manufacturing proceeds.
• Donor exclusion duty: Section 7(4) establishes a duty to not manufacture from donors who meet either of the specified conditions: (a) cumulative residence of six months or more in England, Scotland, Wales, Northern Ireland or the Isle of Man at any time between 1 January 1980 and 31 December 1996; or (b) receipt of a transfusion or injection of blood/blood products while in those places at any time on or after 1 January 1980. Entities must therefore screen donors against these factual criteria and exclude affected donors from manufacturing supply.

Calibrating modification

• Section 7(2) alters a specific element of the Guide by directing that the Guide’s reference to "tropical areas" in relation to a deferral period for "Tropical infections" (in Table 2.2 on page 253 of the Guide) be read not to include areas within Australia. This modifies the operational application of a deferral period contained in the Guide for Australian operations.

Rights and alternative compliance

• Transitional alternative compliance right: Under s 8(2) the former instrument (TGO 81) continues to apply for the transition period (31 March 2019 to 30 March 2020), "such that the standard for blood and blood components constituted by the former instrument may be conformed with as an alternative" to the new standard. This gives manufacturers a time-limited right to choose the former instrument’s requirements rather than the new standard while the transition period lasts.
• Exemptions by fact pattern: The carve outs in s 6(2) function as rights to operate outside the standard in certain clinical and practitioner-led settings. If the blood is collected or manufactured in the course of medical treatment by a registered medical practitioner (or under their supervision), or manufactured by a blood donation centre for a registered practitioner for a particular patient, the standard does not apply (s 6(2)(a)-(c)). Those actors therefore retain the right to rely on state-registration and practitioner-supervision fact patterns to fall outside the federal standard.

Unspecified operational discretions and information gaps

• The instrument is prescriptive in some respects and silent in others. For example, s 7(3) requires nucleic acid amplification testing but does not specify assay sensitivity, pooling strategies, validation parameters, laboratory accreditation or who carries out the test. Those implementation details will be determined by manufacturers, laboratories and regulators in practice, guided by the adopted Guide but not by the Order where the Order is silent.
• The instrument does not articulate enforcement mechanisms, penalties, or reporting obligations. Compliance and enforcement will sit within the Act’s framework (the instrument is made under ss 10 and 36 of the Act (s 3)), but the Order itself does not set out specific sanctioning powers or inspection regimes.

Operational duties arising from incorporated Guide

• Because the Guide’s requirements are incorporated as the major source of substantive obligation (s 7(1)(a)), manufacturers must be alive to the Guide’s content beyond the three express statutory additions. The Guide's requirements on preparation, storage, release criteria, traceability and quality assurance will, by incorporation, create additional duties even though they are not reproduced in the instrument.

In short, the instrument creates concrete duties on manufacturers and blood establishments to adopt the Guide, to apply NAT testing for specified agents, and to exclude donors meeting particular historical residency or transfusion criteria. It also grants time-limited alternative compliance with the repealed instrument and excludes certain practitioner-led clinical activities from its scope. The instrument leaves a range of operational implementation choices and technical specifications to other bodies and documents.

The instrument itself does not set out penalties or a detailed enforcement regime. Its statutory form is a standard constituted under the Therapeutic Goods Act 1989 (see s 5 and s 3, which states the Order is made under ss 10 and 36 of the Act). The Order therefore operates within the Act’s regulatory framework, but it contains no standalone sanctioning provisions.

What the text says and what it leaves to the Act

• Section 3 records the instrument is made under ss 10 and 36 of the Therapeutic Goods Act 1989. The Order does not reproduce or restate the enforcement powers, offences, civil remedies, or administrative sanctions that may be available under the Act. Accordingly, any enforcement, compliance monitoring, sanctions or penalties for non-compliance with the standard will be matters for the Act and the administering regulator under that Act, not for this Order itself.
• Because the instrument does not stipulate penalty amounts, criminal offences or specified administrative actions, the legal consequences of non-compliance must be inferred as actions available under the Act or other statutory instruments referenced by the regulator.

Operational enforcement mechanisms implied by the text

• The Order makes compliance contingent on adopting the Guide and meeting the two express additional requirements in s 7(3) and s 7(4). In practical regulatory terms, enforcement would typically occur through the regulator’s existing functions under the Act in relation to therapeutic goods manufacture, licence conditions, inspections, approvals and adverse event reporting. Those mechanisms are not enumerated here.
• The instrument includes a requirement that certain tests be conducted using a specific technology (nucleic acid amplification technology). Failure to carry out such statutory requirements would be a breach of the standard, and a regulator enforcing the Act would likely characterise that as non-compliance with a mandatory standard. The Order itself does not describe the administrative pathway for remediation, recalls, suspensions, or enforcement action.

Transitional arrangements and enforcement timing

• The transitional arrangement in s 8 allows manufacturers to conform with the former instrument during the transition period (31 March 2019 to 30 March 2020). Enforcement discretion during that period will therefore likely need to account for the alternative compliance permitted by the Order. The transition provision explicitly preserves the former instrument as an acceptable alternative for that period, which modifies the moment at which non-conformity with the new instrument would be actionable.

Discretion and evidentiary questions

• The Order places operational duties on manufacturers to ensure negative NAT results for HBV, HCV and HIV-1 (s 7(3)) and to screen donors against specified residency and transfusion criteria (s 7(4)). Enforcement will require evidence of test results, donor histories and documentary controls. The Order does not supply evidentiary standards, record retention periods or audit pathways, leaving those procedural issues to the wider Act, the adopted Guide, and regulators’ expectations.

Summary

• The Order does not itself provide penalties or a self-contained enforcement regime. It creates mandatory technical and donor-selection obligations, and it sits within the enforcement architecture of the Therapeutic Goods Act 1989, under which the responsible regulator will exercise enforcement powers. Practitioners and manufacturers must therefore review the Act and regulator guidance to determine the precise penalties and enforcement processes that apply to non-compliance with the standard created by TGO 102.

The instrument explicitly situates itself within the broader Therapeutic Goods legal and regulatory framework and modifies inter-instrument references. It also defers to state and territory registration for certain carve outs and incorporates an external technical Guide. The Order therefore interacts with several legal instruments and legal concepts by cross-reference and incorporation.

Primary statutory relationship

• The Order is made under ss 10 and 36 of the Therapeutic Goods Act 1989 (s 3). That places it within the Act’s hierarchy of standards and delegated instruments. The Order does not set out the Act’s enforcement mechanisms, registration regimes, or offence provisions; instead it functions as a standard under the Act. Consequently, the Order’s normative force operates through the Act’s regulatory machinery.

Repeal and transitional interplay with previous TGO

• The Order repeals Therapeutic Goods Order No. 81 - Standards for Blood and Blood Components (Schedule 1; s 9). That is a direct statutory interaction: the replacement of one therapeutic goods order by another alters the corpus of applicable standards.
• Section 8(2) establishes a transition period during which the former instrument "continues to apply" such that conformance with the former instrument "may be conformed with as an alternative" to the new standard. This creates a temporary legal choice of standards for affected parties between two federal instruments.

Consequential amendments to other instruments

• Schedule 2 effects a textual consequential amendment to the Therapeutic Goods (Manufacturing Principles) Determination 2018 by substituting the new Order title in the definition of Technical Master File (Schedule 2, item 1). This ensures internal consistency between the new Order and the manufacturing principles determination, aligning cross-references used in manufacturing documentation frameworks.

Interaction with state and territory law

• The carve outs in s 6(2) rely on the concept of a "medical practitioner, registered under a law of a State or Territory". The Order thereby interacts with state and territory registration regimes for medical practitioners. Whether an activity falls within the s 6(2) exclusion depends on state/territory registration status and whether the collection or manufacture occurs in the course of medical treatment or under a practitioner’s professional supervision. Those determinations implicate state law facts and professional regulation.

Incorporation of an external international standard

• The Order incorporates the Council of Europe Guide (19th ed, 2017) by reference (s 4). That creates an interaction between federal statute and an external technical instrument. The Order fixes the Guide to the version "in force or existing immediately before the commencement" so it does not automatically incorporate later editions. The Order also modifies one specific Guide provision for Australian application (s 7(2)), showing a tailored interaction between imported technical standards and national law.

Operational interplay with manufacturing principles and technical documentation

• The consequential amendment to the Manufacturing Principles determination links the Order to the technical master file and manufacturing principles framework. That ensures that technical documentation obligations and master file arrangements reference the correct current order, which affects manufacturers’ compliance documentation and regulatory submissions.

Silences and implied interactions

• The Order is silent on enforcement, penalties and inspection regimes; these are supplied by the Act and other subordinate instruments. The Order’s duties therefore interact implicitly with the Act’s compliance and enforcement apparatus, record keeping requirements, licensing requirements and other regulatory instruments not reproduced here.

Temporal interactions and historical criteria

• Section 7(4) imposes donor eligibility exclusions that turn on historical residence and transfusion/injection activities in specific foreign jurisdictions within defined date ranges. These are interactions between current manufacturing regulation and factual histories that cross territorial and temporal boundaries. They require manufacturers to collect or verify past information about donors that touches on immigration and medical history.

In sum, TGO 102 interacts with: the Therapeutic Goods Act 1989 by being constituted under it; the repealed TGO 81 by replacing it while temporarily preserving it as an alternative; the Manufacturing Principles Determination by a consequential amendment; state/territory medical registration regimes through the carve outs; and the Council of Europe Guide by incorporating a fixed edition. The Order leaves operational enforcement, penalties and many implementation details to the Act, the Guide, and other regulatory instruments.

The instrument itself records the immediate amendments and repeals it effects, and provides commencement and transitional details. There are no entries in the text about subsequent amendments beyond the consequential change to another instrument.

Key dates and making

• The instrument was made by the delegate of the Minister for Health and is dated 22 March 2019 (front matter). It names the delegate who made the Order, Jane Cook, First Assistant Secretary, Medicines Regulation Division, Health Products Regulation Group, Department of Health.
• The instrument’s commencement is specified in section 2. The entire instrument is taken to have commenced on 31 March 2019 (s 2(1) and the commencement table).

Repeals and substitutions effected by the instrument

• Schedule 1 repeals Therapeutic Goods Order No. 81 - Standards for Blood and Blood Components. Section 9 declares that each instrument in Schedule 1 is repealed as set out in the Schedule; Schedule 1 then specifies that "The whole of the instrument" TGO 81 is repealed (Schedule 1, item 1).
• Schedule 2 makes a consequential amendment to the Therapeutic Goods (Manufacturing Principles) Determination 2018 by substituting the reference to the former instrument with the new instrument’s title in the definition of Technical Master File (Schedule 2, item 1).

Transitional arrangement

• Section 8 establishes a transition period from 31 March 2019 to 30 March 2020. During this period the former instrument continues to apply such that conformance with the former standard may be relied on as an alternative to conformance with the new standard (s 8(2)). The Order thereby provides a one-year window in which affected parties can choose to comply with either the prior or the new instrument.

No recorded later amendments in the text

• The text supplied contains no entries for later amendments to TGO 102 beyond its initial making, commencement, repeal of TGO 81, the transitional arrangement and the consequential amendment to the Manufacturing Principles Determination. There is no schedule of amendments, no amendment dates beyond commencement, and no mention of future variation mechanisms within the Order’s text.

Document versioning and Guide version fixation

• The instrument fixes the Guide to the 19th edition, 2017 "as in force or existing immediately before the commencement of this instrument" (s 4). That is an important temporal lock: future editions of the Guide are not automatically incorporated by the Order. Any future amendment of the Order would be needed to adopt a later Guide edition or to alter the statutory additions.

Practical implication of the amendment architecture

• The Order both replaces and temporarily co-exists with the previous standard, and it updates a cross-reference in the manufacturing principles instrument. Any later amendment to this Order would need to be reflected in related instruments where it is referenced. For now, the amendment history recorded in the instrument is limited to the replacement of TGO 81 and the single consequential textual substitution in the Manufacturing Principles Determination.

The instrument text does not record any litigation history. There are no cases, appeals, or judicial decisions cited in the Order itself.

What the text supplies

• The Order comprises an administrative standard and schedules of repeal and consequential amendment. It contains no references to judicial interpretation, no saved case law citations, and no litigation-related provisos.

Consequences of the silence

• Because the instrument contains no litigation history, readers should not infer that the instrument has been subject to judicial scrutiny, quashed, or interpreted in litigation. The absence of litigation references in the instrument does not preclude subsequent judicial challenges or disputes; it simply means the instrument as made contains no such history.

Practical note for users

• Practising lawyers, compliance officers and risk managers relying on this instrument should consult external legal databases, regulatory guidance and the Therapeutic Goods Act 1989 records for any post-making litigation, judicial review, or tribunal decisions that may have interpreted or affected the operation of TGO 102. The instrument itself does not supply any such material.

If litigation arises, likely issues

• While not present in the text, typical areas where litigation or regulatory dispute might arise in instruments of this kind include: disputes over whether particular activities fall within the s 6(2) carve outs; challenges to the application of s 7(4) donor exclusions in particular factual scenarios; or contention over what constitutes adequate implementation of the s 7(3) nucleic acid amplification testing requirement. The instrument, however, contains no litigation record to report.

This short instrument contains specific textual choices and cross-references that create potential traps for practitioners and operators. Below are concrete points that require attention, each grounded in the instrument’s text.

1. The Guide is adopted but fixed to a single edition

• The instrument adopts the Council of Europe Guide, 19th edition, 2017, "as in force or existing immediately before the commencement of this instrument" (s 4). That fixes the applicable Guide version to the pre-commencement state. Users must therefore ensure they are reading and complying with that edition, not a later edition, unless the Order is amended. The instrument does not provide for automatic adoption of later editions.

2. Narrow definitions that exclude some products

• Blood is defined as "whole blood collected from a single human donor and processed either for transfusion or further manufacturing" (s 4). Blood components are limited to those prepared "by centrifugation, filtration or freezing using conventional methodologies in blood establishment" and explicitly exclude haematopoietic progenitor cells (s 4). Products that fall outside these definitions may not be captured by the Order; conversely, manufacturers must verify that their product fits within these definitions before applying the Order’s requirements.

3. The "tropical areas" modification

• Section 7(2) instructs that the Guide’s reference to "tropical areas" in relation to the deferral period for the condition "Tropical infections" is not to include areas within Australia. This creates an Australia-specific calibration of a Guide deferral, affecting donor deferrals for tropical infection risk. Practitioners must ensure their internal deferral policies adopt the modified reading rather than the Guide’s unmodified text.

4. Specific testing methodology required but details omitted

• Section 7(3) requires negative testing for HBV, HCV and HIV-1 "using nucleic acid amplification technology." The Order does not specify assay sensitivity, pooling protocols, validation or accreditation standards. The Guide may provide operational guidance, but the Order itself leaves these specifics open. Practitioners must determine acceptable testing regimes and document validation and quality assurance in line with the Guide and regulator expectations.

5. Donor exclusion wording and a literal textual oddity

• Section 7(4)(a) excludes donors who lived in, or visited, England, Scotland, Wales, Northern Ireland or the Isle of Man for a cumulative period of six months or more "at any time on or between 1 January 1980 and 31 December 1996." Section 7(4)(b) excludes donors who received a transfusion or injection of blood or blood products "while in England, Scotland, Wales, Northern Island or the Isle of Man" "at any time on or after 1 January 1980." The instrument contains a printed reference to "Northern Island" in s 7(4)(b). Users should apply the textual wording as printed, but in practice may need to confirm whether that is a typographical issue to be resolved by legislative amendment or administrative guidance.

6. Transition period offers an alternative compliance pathway

• For the transition period (31 March 2019 to 30 March 2020) the former instrument continues to apply as an alternative (s 8(2)). Failure to take account of that option could lead to unnecessary compliance upheaval; however, reliance on the former instrument is time-limited. After the transition period, the new instrument applies and TGO 81 is repealed (s 9; Schedule 1).

7. Scope exclusions hinge on state registration and professional supervision

• The s 6(2) exclusions require a medical practitioner "registered under a law of a State or Territory" or a person "under the professional supervision of such a practitioner." Those are factual predicates that can be contested. Record-keeping and evidence of registration and supervision are therefore practical necessities where the parties seek to rely on the carve outs.

8. The Order is silent on enforcement mechanics and penalty specifics

• The instrument does not specify penalties, inspection rights or remediation mechanisms. Enforcement will come through the Act under which the Order is made (s 3). Operators must therefore consult the Act and regulators’ compliance guidance to understand enforcement risk and reporting obligations.

9. Cross-references must be updated in technical documentation

• Schedule 2 substitutes the new Order title in the Manufacturing Principles Determination 2018. Manufacturers should ensure their technical master files, submissions and standard operating procedures reference TGO 102 rather than TGO 81 where relevant, and confirm any internal documents rely on the correct instrument.

10. Ambiguities on implementation detail

• The Order prescribes certain outcomes (negative NAT results, donor exclusions) but not the operational mechanics for achieving them. Decision-makers must implement procedures, validations and documentary controls consistent with the adopted Guide and be prepared to justify choices where the Order is silent.

Practically, these "gotchas" mean legal, quality and operations teams must cross-check definition scopes, update master files and SOPs, calibrate deferral policies to s 7(2), document NAT testing implementation and retain documentary proof for the carve outs under s 6(2). Where textual oddities appear (for example, "Northern Island"), operators should seek administrative clarification and preserve documentary evidence of their interpretive approach.

Compliance with the Order requires a combination of documentary alignment, operational testing changes, donor screening procedures and transitional decision-making. The steps below are grounded in the instrument’s requirements and its incorporation of the Guide.

1. Establish authoritative documentary foundation

• Obtain and adopt the Council of Europe Guide to the preparation, use and quality assurance of blood components, 19th edition, 2017 (the Guide) "as in force or existing immediately before the commencement" (s 4). Ensure the exact edition and relevant pages (for example Table 2.2 at page 253 referenced in s 7(2)) are in your controlled documents.
• Update organisational policies, standard operating procedures, master files and regulatory submissions to reference Therapeutic Goods (Standard for Blood and Blood Components) (TGO 102) Order 2019 rather than TGO 81, in line with Schedule 2.

2. Decide whether to use the transition alternative

• Between 31 March 2019 and 30 March 2020 (the transition period defined in s 8) you may elect to conform with the former instrument (TGO 81) as an alternative (s 8(2)). Make an explicit business decision, document it, and maintain records of the basis for the choice and the transition timeline. If you elect to use the former standard during the transition period, plan for switching to TGO 102 once the transition ends.

3. Implement the NAT testing requirement

• Section 7(3) requires that blood and blood components be manufactured only from blood where samples test negative for HBV, HCV and HIV-1 using nucleic acid amplification technology. Therefore:
  • Establish validated NAT assays for HBV, HCV and HIV-1 or procure accredited laboratory services that perform those assays.
  • Define and document the testing algorithm, including sample collection points, acceptance criteria, turnaround times and the negative-result requirement prior to manufacture.
  • Maintain records of NAT results linked to donor identifiers and batches to support release decisions and traceability.
  • Where the Guide provides further technical guidance on testing, align laboratory validation, quality control and accreditation with the Guide and with the regulator’s expectations.

4. Implement donor screening and exclusion rules

• Adopt procedures to capture historical donor information relevant to s 7(4). Specifically:
  • For residence-based exclusion: screen donors for cumulative periods of six months or more in England, Scotland, Wales, Northern Ireland or the Isle of Man between 1 January 1980 and 31 December 1996 (s 7(4)(a)). Implement intake questions, documentation requirements and verification protocols to support the exclusion decision.
  • For transfusion/injection-based exclusion: screen donors for history of receiving transfusion or injection of blood or blood products while in those same places "at any time on or after 1 January 1980" (s 7(4)(b)). Maintain records of responses and the decisions to exclude or accept donors.
  • Because s 7(4)(b) contains the printed wording "Northern Island" ensure the factual capture process accounts for variations in spelling and geographic names and retain any administrative clarifications you rely on.

5. Apply the "tropical areas" modification

• In donor deferral policies or risk assessments referencing Table 2.2 of the Guide, treat the Guide’s reference to "tropical areas" for the deferral period for "Tropical infections" as not including areas within Australia (s 7(2)). Document that this is a statutory modification and ensure deferral practices reflect the instrument’s reading.

6. Update technical master files and regulatory submissions

• Where your Technical Master File, Manufacturing Principles compliance documentation, or other regulated documents cite the prior instrument, update those citations to refer to TGO 102 as per Schedule 2. Ensure continuity of technical documentation and that submissions to the regulator correctly reference the current standard.

7. Evidence and record-keeping

• Maintain auditable records demonstrating:
  • Which standard you relied on during the transition period and when you switched (if applicable).
  • NAT results with linkage to donor and batch and confirmation that negative results preceded manufacturing release decisions.
  • Donor screening questionnaire responses, verification documents and exclusion rationales per s 7(4).
  • Training records showing staff awareness of the new standard, the Guide edition adopted and the s 7(2) modification regarding tropical areas.

8. Quality systems and audit

• Integrate the Order’s requirements into quality management systems and internal audit cycles. Because the Order adopts the Guide as the primary substantive requirement, your quality system should map Guide provisions to internal controls and to compliance evidence meeting s 7(1)(a).

9. Liaise with regulators for interpretive ambiguities

• For implementation questions left open by the Order (for example, NAT pooling practices, assay sensitivity thresholds, specific documentary evidence of residency or transfusion history, or the textual oddity in s 7(4)(b)), engage early with the regulator to seek clarification or to obtain formal guidance rather than relying on unilateral interpretations. Retain records of any regulatory correspondence relied on for compliance decisions.

10. Coordinate with clinical services

• For hospital transfusion services and clinical blood banks, ensure clinical procedures and transfusion policies align with donor exclusions and testing regimes to avoid supply interruptions. Where the s 6(2) carve outs might apply (practitioner-collected or practitioner-manufactured blood for particular patients), confirm the factual predicates and maintain documentation demonstrating applicability of the carve out.

By following these steps, an operator will be aligning operational practice with the express statutory requirements in TGO 102 (ss 4, 6, 7), the adopted Guide (s 7(1)(a)), and the transitional and consequential amendment provisions (s 8; Schedule 2). The Order leaves a number of technical implementation details to the Guide and to regulator expectations; compliance programmes should therefore triangulate the Order, the Guide and any applicable guidance from the administering authority.